Cannabis as a substitute for prescription drugs - a cross-sectional study

被引:161
作者
Corroon, James M., Jr. [1 ]
Mischley, Laurie K. [2 ]
Sexton, Michelle [3 ]
机构
[1] Ctr Med Cannabis Educ, 428 8th St, Del Mar, CA 92014 USA
[2] Bastyr Univ, Res Inst, Kenmore, WA USA
[3] Ctr Study Cannabis & Social Policy, Dept Med Res, Seattle, WA USA
来源
JOURNAL OF PAIN RESEARCH | 2017年 / 10卷
关键词
cannabis; marijuana; prescription drugs; pain; analgesics; opioid; PATIENT-REPORTED OUTCOMES; MEDICAL CANNABIS; CHRONIC PAIN; SEX-DIFFERENCES; MENTAL-HEALTH; MARIJUANA; OPIOIDS; SUBSTANCES; EXPOSURE; ALCOHOL;
D O I
10.2147/JPR.S134330
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The use of medical cannabis is increasing, most commonly for pain, anxiety and depression. Emerging data suggest that use and abuse of prescription drugs may be decreasing in states where medical cannabis is legal. The aim of this study was to survey cannabis users to determine whether they had intentionally substituted cannabis for prescription drugs. Methods: A total of 2,774 individuals were a self-selected convenience sample who reported having used cannabis at least once in the previous 90 days. Subjects were surveyed via an online anonymous questionnaire on cannabis substitution effects. Participants were recruited through social media and cannabis dispensaries in Washington State. Results: A total of 1,248 (46%) respondents reported using cannabis as a substitute for prescription drugs. The most common classes of drugs substituted were narcotics/opioids (35.8%), anxiolytics/benzodiazepines (13.6%) and antidepressants (12.7%). A total of 2,473 substitutions were reported or approximately two drug substitutions per affirmative respondent. The odds of reporting substituting were 4.59 (95% confidence interval [CI], 3.87-5.43) greater among medical cannabis users compared with non-medical users and 1.66 (95% CI, 1.27-2.16) greater among those reporting use for managing the comorbidities of pain, anxiety and depression. A slightly higher percentage of those who reported substituting resided in states where medical cannabis was legal at the time of the survey (47% vs. 45%, p=0.58), but this difference was not statistically significant. Discussion: These patient-reported outcomes support prior research that individuals are using cannabis as a substitute for prescription drugs, particularly, narcotics/opioids, and independent of whether they identify themselves as medical or non-medical users. This is especially true if they suffer from pain, anxiety and depression. Additionally, this study suggests that state laws allowing access to, and use of, medical cannabis may not be influencing individual decision-making in this area.
引用
收藏
页码:989 / 997
页数:9
相关论文
共 51 条
[1]  
[Anonymous], 2013, SURVEY CANNABIS USE
[2]   Simultaneous alcohol and cannabis expectancies predict simultaneous use [J].
Barnwell, Sara Smucker ;
Earleywine, Mitch .
SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY, 2006, 1 (1)
[3]   The Missing Voice of Patients in Drug-Safety Reporting [J].
Basch, Ethan .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (10) :865-869
[4]   Modulation of Mediotemporal and Ventrostriatal Function in Humans by Δ9-Tetrahydrocannabinol A Neural Basis for the Effects of Cannabis sativa on Learning and Psychosis [J].
Bhattacharyya, Sagnik ;
Fusar-Poli, Paolo ;
Borgwardt, Stefan ;
Martin-Santos, Rocio ;
Nosarti, Chiara ;
O'Carroll, Colin ;
Allen, Paul ;
Seal, Marc L. ;
Fletcher, Paul C. ;
Crippa, Jose A. ;
Giampietro, Vincent ;
Mechelli, Andrea ;
Atakan, Zerrin ;
McGuire, Philip .
ARCHIVES OF GENERAL PSYCHIATRY, 2009, 66 (04) :442-451
[5]   Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain [J].
Boehnke, Kevin F. ;
Litinas, Evangelos ;
Clauw, Daniel J. .
JOURNAL OF PAIN, 2016, 17 (06) :739-744
[6]   Medical Marijuana Laws Reduce Prescription Medication Use In Medicare Part D [J].
Bradford, Ashley C. ;
Bradford, W. David .
HEALTH AFFAIRS, 2016, 35 (07) :1230-1236
[7]   Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders [J].
Campos, Alline Cristina ;
Moreira, Fabricio Araujo ;
Gomes, Felipe Villela ;
Del Bel, Elaine Aparecida ;
Guimaraes, Francisco Silveira .
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2012, 367 (1607) :3364-3378
[8]  
CDC, OP PAINK PRESCR VIT
[9]  
Center for Behavioral Health Statistics and Quality, 2016, HHS PUBL, VH-51
[10]  
Center for Behavioral Health Statistics and Quality, 2015, RES 2015 NAT SURV DR